Target detail
ENG
endoglin
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: endoglin
Aliases: ENG, endoglin
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000106991
Index freshness: last_synced_at 2026-05-15T20:09:57.844+00:00 · updated 2026-05-15T20:09:58.453434+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ENG. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT02669173 — Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00979862 — Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00813943 — Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01124240 — Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT00104091 — Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00704080 — A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03603379 — Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02664363 — EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT01782976 — Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
Status: WITHDRAWN · clinicaltrials.gov
Open trials hubNCT05131815 — The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01870726 — Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT03970447 — A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 13
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.